Leah R. Neufeld - 13 Mar 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: CHIEF PEOPLE OFFICER
Issuer ticker: IMRX
Reported as of: 13 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Mar 2026, 16:46:41 UTC
Prior SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael D. Bookman, Attorney-in-Fact for Leah R. Neufeld

Key filing fact

Leah R. Neufeld filed Form 4 for Immuneering Corp (IMRX) on 17 Mar 2026.

Key facts

This page summarizes Leah R. Neufeld's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Mar 2026, 16:46.

Change

Previous filing in this sequence was filed on 05 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001950673 Primary reporting owner

Neufeld Leah R

Relationship: CHIEF PEOPLE OFFICER
Address: 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Leah R. Neufeld
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMRX transaction

Class A Common Stock

Award

Transaction value
Shares: +3,628
Change %: +14%
Price: $4.29^*
Shares after: 29,598
Date: 13 Mar 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 16, 2025 through March 15, 2026. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.

Footnote F2

The relevant Offering Period (as defined in the ESPP) ended on March 15, 2026. The shares were acquired on the Purchase Date (as defined in the ESPP) of March 13, 2026.

Footnote F3

In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of the relevant Offering Period.